Abstract
Angiogenesis generally plays an essential role in tumor growth and metastasis, and also influences the response to treatment in human malignant solid tumors. Even in nonmalignant tumors, angiogenesis is essential for tumor growth and invasion. In order to define the relationship between tumor vascularity and the clinical course in patients with pituitary adenomas, we quantified the vascularity in 47 pituitary adenomas and in 6 normal anterior pituitary glands obtained at autopsy using a computed image-analyzing system. We estimated two parameters, the vascular number and the area as the vascularity. Additionally, we calculated mean individual vessel size using the above two parameters. The relationships of tumor vascularity to clinical, endocrinological and histological findings was assessed. Factors considered included patient age and gender, preoperative medication, histological type, concentration of each hypersecreted pituitary hormone, maximum tumor size, cavernous sinus invasion, intratumoral hemorrhage, and immunohistological results of localization of vascular endothelial growth factor (VEGF). Vascularity was significantly higher in normal glands than in pituitary adenomas. However, there were no significant correlations between tumor vascularity and other clinical, endocrinological, or histological parameters, suggesting that increased angiogenesis is not essential for pituitary adenoma growth or invasiveness.
Similar content being viewed by others
References
Risau W. Mechanisms of angiogenesis. Nature 386:671–674, 1997.
Folkman J, Shing Y. Angiogenesis. J Biol Chem 267:10931–10934, 1992.
Weidner N, Semple JP, Welch WR, Folkman J. Tumor angiogenesis and metastasis: correlation in invasive breast carcinoma. N Engl J Med 324:1–8, 1991.
Bochner BH, Cote RJ, Weidner N, et al. Angiogenesis in bladder cancer: relationship between microvessel density and tumor prognosis. J Natl Cancer Inst 87:603–612, 1995.
Gasparini G, Bevilacqua P, Bonoldi E, Testolin A, Galassi A, Verderio P. Predictive and prognosis markers in a series of patients with head and neck squamous-cell invasive carcinoma treated with concurrent chemoradiation therapy. Clin Can Res 1:1375–1383, 1995.
Bosan S, Lee AK, DeLellis RA, Wiley BD, Heatley GJ, Silverman ML. Microvessel quantitation and prognosis in invasive breast carcinoma. Hum Pathol 23:755–761, 1992.
Visscher DW, Smilanetz S, Drozdovicz S, Wykes SM. Prognostic significance of image morphometric microvessel enumeration in breast carcinoma. Anal Quant Cytol Histol 15:88–92, 1993.
Weidner N, Folkman J, Pozza F, et al. Tumor angiogenesis: a new significant and independent prognostic indicator in early stage breast carcinoma. J Natl Cancer Inst 84:1875–1887, 1992.
Plate KH, Breier GH, Weich HA, Risau W. Vascular endothelial growth factor is a potential tumor angiogenesis factor in human gliomas in vivo. Nature 359:845–848, 1992.
Berkman RA, Merrill MJ, Reinhold WC, et al. Expression of the vascular permeability factor/vascular endothelial growth factor gene in central nervous system neoplasms. J Clin Invest 91:153–159, 1993.
Berse B, Brown LF, Van de Vater L, Dvorak HF, Senger DR. Vascular permeability factors (vascular endothelial growth factor) gene is expressed differentially in normal tissues, macrophages, and tumors. Mol Biol Cell 3:211–220, 1992.
Jugenburg M, Kovacs K, Stefaneanu L, Scheithauer BW. Vasculature in nontumorous hypophyses, pituitary adenomas, and carcinomas: a quantitative morphological study. Endocr Pathol 6:115–124, 1995.
Erroi A, Bassetti M, Spada A, Giannattasio G. Microvasculature of human micro- and macroprolactinomas. Neuroendocrinology 43:159–165, 1986.
Pawlikowski M, Pisaret H, Jaranowska M. Immunocytochemical investigations on the vascularization of pituitary adenomas. Endocr Pathol 8:189–193, 1997.
Vidal S, Kovacs K, Horvath E, Scheithauer BW, Kuroki T, Lloyd RV. Microvessel density in pituitary adenomas and carcinomas. Virchows Arch 438:595–602, 2001.
Turner HE, Nagy Z, Gatter KC, Esiri MM, Harris AL, Wass JAH. Angiogenesis in pituitary adenomas—relationship to endocrine function, treatment and outcome. Clin Endocrino 165:475–481, 2000.
Iuchi T, Saeki N, Osato K, Yamaura A. Proliferation, vascular endothelial growth factor expression and cavernous sinus invasion in growth hormone secreting pituitary adenomas. Acta Neurochir (Wien) 142:1345–1351, 2000.
Lloyd RV, Scheithauer BW, Kuroki T, Vidal S, Kovacs K, Stefaneau L. Vascular endothelial growth factor (VEGF) expression in human pituitary adenomas and carcinomas. Endocr Pathol 10:229–235, 1999.
Turner HE, Nagy Z, Gatter KC, Esiri MM, Harris AL, Wass JAH. Angiogenesis in pituitary adenomas and the normal pituitary gland. J Clin Endocrinol Meta 85:1159–1162, 2000.
Lohrer P, Gloddek J, Hopfiner U, et al. Vascular endothelial growth factor production and regulation in rodent and human pituitary tumor cells in vitro. Neuroendocrinology 74:95–105, 2001.
Viacava P, Gasperi M, Acerbi G, et al. Microvascular density and vascular endothelial growth factor expression in normal pituitary tissue and pituitary adenomas. J Endocrinol Invest 26:23–28, 2003.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Takada, K., Yamada, S. & Teramoto, A. Correlation between tumor vascularity and clinical findings in patients with pituitary adenomas. Endocr Pathol 15, 131–139 (2004). https://doi.org/10.1385/EP:15:2:131
Issue Date:
DOI: https://doi.org/10.1385/EP:15:2:131